Search

Displaying results 6901 - 6910 of 10000 in total
  1. Drug

    Rupitasertib

    go.drugbank.com/drugs/DB15431
    Investigational

    M-2698 is under investigation in clinical trial NCT01971515 (First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies).

  2. Drug

    SYNB1353

    go.drugbank.com/drugs/DB17666
    Investigational

    SYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug. … It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983]

  3. Drug

    Abdavomeran

    go.drugbank.com/drugs/DB15695
    Investigational

    [L15012] BNT162b1 is undergoing further evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701). … [L15007, L15012] Early results from a phase 1/2 study in 45 healthy adult volunteers demonstrated RBD-binding immunoglobulin levels and 50% serum neutralizing titers higher than those observed in [COVID

    Categories: Complex Mixtures
  4. Drug

    Telatinib

    go.drugbank.com/drugs/DB15393
    Investigational

    Telatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).

  5. Drug

    Chiauranib

    go.drugbank.com/drugs/DB16124
    Investigational

    Chiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed/refractory Non-hodgkin's Lymphoma).

  6. Drug

    Methscopolamine bromide

    go.drugbank.com/drugs/DB00462
    Approved

    A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.

    Synonyms: N-methylhyoscine bromide, N-methylscopolammonium bromide
  7. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  8. Drug

    Lomefloxacin

    go.drugbank.com/drugs/DB00978
    Approved

    Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.

  9. Drug

    Roxithromycin

    go.drugbank.com/drugs/DB00778
    ApprovedInvestigationalWithdrawn

    It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections. … It was shown to be more effective against certain Gram-negative bacteria, particularly _Legionella pneumophila_.

    International brands: Le Er Tai, Ren Su
  10. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic